EDAP TMS and Telix Pharmaceuticals will explore a joint clinical research collaboration focused on the management of prostate cancer.
Under an agreement, the companies will focus on combining EDAP’s Focal One Robotic HIFU treatment and Telix’s prostate-specific membrane antigen (PSMA) PET imaging agents in the management of prostate cancer. The goal is to optimize treatment planning, deliver a precise, image-guided focal therapy treatment, and monitor responses after treatment and during subsequent patient follow-up, EDAP said. This collaboration will be investigated in both the primary treatment setting as well as the salvage treatment setting after radiation therapy.
The parties may also explore clinician education programs, including webinars and training initiatives, according to the announcement.
